Scarica l'app Stockscreener
3.1775
2.84%
0.0075
Precedente Chiudi:
$3.17
Aprire:
$3.17
Volume 24 ore:
379.36K
Relative Volume:
0.31
Capitalizzazione di mercato:
$1.88M
Reddito:
-
Utile/perdita netta:
$-24.83M
Rapporto P/E:
-0.1226
EPS:
-25.91
Flusso di cassa netto:
$-13.27M
1 W Prestazione:
-5.51%
1M Prestazione:
-72.37%
6M Prestazione:
+858.82%
1 anno Prestazione:
+183.48%
Intervallo 1D:
$3.07
$3.3999
Intervallo di 1 settimana:
$2.95
$3.56
Portata 52W:
$0.2654
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Nome
Windtree Therapeutics Inc
Settore
Industria
Telefono
(215) 488-9300
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-26 | Iniziato | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
Understanding WINT stock ratios for better investment decisions - US Post News
WINT’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
In the Green: Windtree Therapeutics Inc (WINT) Closes at 3.45, Up/Down 23.21 from Previous Day - The Dwinnex
Windtree Therapeutics Advances Heart Failure Treatment with SEISMiC Extension Study Completion - MSN
Windtree Therapeutics Advances Heart Failure Treatment with SEISMiC Extension Study Completion - MyChesCo
Take off with Windtree Therapeutics Inc (WINT): Get ready for trading - SETE News
WINT stock touches 52-week low at $2.8 amid sharp annual decline - Investing.com
WINT stock touches 52-week low at $2.8 amid sharp annual decline - Investing.com Canada
Market Insights: Windtree Therapeutics Inc (WINT)’s Notable Gain of 4.08, Closing at 3.32 - The Dwinnex
Windtree Therapeutics Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
What's Going On With Windtree Therapeutics Stock Wednesday? - Benzinga
Windtree (WINT) Stock Climbs In Pre-Market Trading After Major Update - Stocks Telegraph
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock - GlobeNewswire
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock - StockTitan
When the Price of (WINT) Talks, People Listen - Stock Traders Daily
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 56.8% in August - Defense World
Analyzing Windtree Therapeutics (NASDAQ:WINT) & ZIVO Bioscience (NASDAQ:ZIVO) - Defense World
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates - MSN
Windtree Therapeutics Reports Second-Quarter Financial Results and Key Business Updates - MyChesCo
Windtree Therapeutics (NASDAQ:WINT) Issues Quarterly Earnings Results, Misses Expectations By $12.80 EPS - Defense World
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewswire
Windtree Therapeutics reports Q2 EPS ($20.91) vs. ($29.47) last year - TipRanks
WINT Stock Earnings: Windtree Therapeutics Reported Results for Q1 2024 - InvestorPlace
Sorrento Therapeutics (OTC:SRNE) Stock Quotes, Forecast and News Summary - Benzinga
Windtree Therapeutics Announces New Board Appointments - MyChesCo
Windtree Therapeutics announces board changes - Investing.com India
Windtree Announces New Additions and Changes to Its Board of Directors - GlobeNewswire
Windtree Therapeutics reshapes board with new directors - Investing.com India
Windtree Therapeutics announces board changes By Investing.com - Investing.com Canada
Windtree Therapeutics announces board changes - Investing.com
Windtree Therapeutics announces board changes By Investing.com - Investing.com Australia
Windtree Therapeutics announces board changes By Investing.com - Investing.com UK
Windtree Therapeutics reshapes board with new directors - Investing.com
Windtree Therapeutics Board Reshuffles, Appoints New Directors - TipRanks
Windtree Announces New Additions and Changes to Its Board of Directors - StockTitan
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Grows By 455.6% - Defense World
What's Going On With Windtree Therapeutics Stock? - MSN
Trading Day Review: Windtree Therapeutics Inc (WINT) Gains Momentum, Closing at 9.12 - The Dwinnex
Why Windtree Therapeutics (WINT) Stock Is Volatile Today - MSN
Windtree Therapeutics Inc: Analyzing WINT Stock Trends - The InvestChronicle
Windtree secures $1M in private placement deal By Investing.com - Investing.com Canada
Windtree secures $1M in private placement deal - Investing.com
Windtree secures $1M in private placement deal By Investing.com - Investing.com Nigeria
Windtree secures $1M in private placement deal - Investing.com India
Why Windtree Therapeutics (WINT) Stock Is Volatile Today - Benzinga
A closer look at Windtree Therapeutics Inc’s (WINT) current quarter earnings projections - US Post News
Holdings of Windtree Therapeutics Inc (WINT) are aligned with the stars - SETE News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Decreases By 17.5% - Defense World
Windtree Therapeutics (WINT) Advancing Cardiac Innovation with Istaroxime - BP Journal
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials - MyChesCo
Should investors be concerned about WINT’s high price-to-sales ratio? - US Post News
Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Windtree Therapeutics Inc Azioni (WINT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fraser Craig | President and CEO |
Sep 26 '23 |
Buy |
0.90 |
2,500 |
2,250 |
55,377 |
1.26%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):